THYME AND CARVACROLL Nanoparticle Effect on Fungi

Invasive Aspergillosis (IA) has increasingly been recognized as an emerging disease of non-neutropenic patients and in patients admitted to the ICU, even in the absence of an apparent predisposing immune-deficiency, with incidence ranges from 0.3% to 5.8% with an overall mortality rate exceeding 80%.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aspergillosis Bacterial Infections and Mycoses Infections Mycoses

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut university

Asyut, 71111, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

intensive care patients

Exclusion criteria

none

Treatment and study plan

silver nanoparticle

Other

fungicidal effect of silver nanoparticles on aspergillus isolates

Primary outcomes

fungicidal effect of silver nanoparticles on aspergillus fumigatus

Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Effect of Thyme and Carvacroll Nanoparticles on Aspergillus Fumigatus Isolate From Intensive Care Patients

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Jun 16, 2020
Registry last updated: Nov 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed